Solventum Corp. (SOLV)
Pretax margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|
Earnings before tax but after interest (EBT) | US$ in thousands | 910,000 | 1,692,000 | 1,882,000 | 1,440,000 |
Revenue | US$ in thousands | 8,241,000 | 8,130,000 | 8,171,000 | 7,281,000 |
Pretax margin | 11.04% | 20.81% | 23.03% | 19.78% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $910,000K ÷ $8,241,000K
= 11.04%
Solventum Corp.'s pretax margin has shown a declining trend over the past three years. In 2023, the pretax margin decreased significantly to 11.04% from 20.81% in 2022. This decline may indicate challenges in controlling costs or generating revenue efficiently. Furthermore, compared to 2021 and 2020, where the pretax margin was 23.03% and 19.78%, respectively, the company's profitability has weakened in the most recent year. Management should investigate the reasons behind this decline and consider implementing strategies to improve efficiency and profitability in the future.
Peer comparison
Dec 31, 2023
Company name
Symbol
Pretax margin
Solventum Corp.
SOLV
11.04%
3M Company
MMM
-29.64%
Artivion Inc
AORT
-6.52%
Baxter International Inc
BAX
17.66%
Becton Dickinson and Company
BDX
8.34%
Boston Scientific Corp
BSX
14.20%
DexCom Inc
DXCM
19.72%
Embecta Corp
EMBC
9.51%
Glaukos Corp
GKOS
-44.40%
Globus Medical
GMED
10.54%
Haemonetics Corporation
HAE
5.85%